Abstract
In recent years, there has been a substantial increase in the development of antitussive therapies and the first new therapy, gefapixant has been licenced in Europe. This review describes current unlicenced treatments for chronic cough and details treatments currently in development for refractory chronic cough and cough in idiopathic pulmonary fibrosis, as well as compounds previously explored.
Original language | English |
---|---|
Pages (from-to) | 5-16 |
Number of pages | 12 |
Journal | Lung |
Volume | 202 |
Issue number | 1 |
Early online date | 21 Dec 2023 |
DOIs | |
Publication status | Published - 1 Feb 2024 |
Keywords
- Antitussives
- Idiopathic pulmonary fibrosis
- P2X3 antagonists
- Refractory chronic cough